×
About 1,933 results

ALLMedicine™ Cardiovascular Risk Reduction Center

Research & Reviews  845 results

Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2...
https://doi.org/10.1161/JAHA.120.016835
Journal of the American Heart Association; Nelson AJ, Ardissino M et. al.

Jan 12th, 2021 - Background Evidence-based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results Pharmac...

Triglycerides as target of cardiovascular risk reduction.
https://doi.org/10.1097/MOL.0000000000000724
Current Opinion in Lipidology FURTHER RECOMMENDED READING; Tietge UJF

Dec 28th, 2020 - Triglycerides as target of cardiovascular risk reduction.|2020|Tietge UJF,|

Advances in the management of statin myopathy.
https://doi.org/10.1097/MED.0000000000000595
Current Opinion in Endocrinology, Diabetes, and Obesity; Gallo A, Perregaux J et. al.

Dec 5th, 2020 - Statins are highly effective therapies for reducing low-density lipoprotein cholesterol and preventing cardiovascular events. However, many patients taking statins experience statin-associated muscle symptoms. In the current manuscript, we review ...

EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.
https://doi.org/10.1016/S2213-8587(20)30368-5
The Lancet. Diabetes & Endocrinology; Aroda VR, Sabatine MS

Nov 20th, 2020 - EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.|2020|Aroda VR,Sabatine MS,|

Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications...
https://doi.org/10.1016/j.jacc.2020.09.004
Journal of the American College of Cardiology; Januzzi JL, Xu J et. al.

Oct 30th, 2020 - Canagliflozin reduces cardiovascular events including hospitalization for heart failure (HHF) in patients with type 2 diabetes and cardiovascular risk. Elevated amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associate...

see more →

Guidelines  55 results

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545583
Journal of the American College of Cardiology; Das SR, Everett BM et. al.

Aug 10th, 2020 - 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.|2020|Das SR,Everett BM,Birtcher KK,Brown...

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
http://www.onlinejacc.org/content/early/2019/03/07/j.jacc.2019.03.010
Journal of the American College of Cardiology;

Mar 16th, 2019 - Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally (S1- 1–S1-3). In the United States, it is also the le...

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext

Feb 1st, 2019 - Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large sta...

Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events
https://jamanetwork.com/journals/jama/article-abstract/2721178
Zheng,S.,et al

Jan 21st, 2019 - Question: What is the association of aspirin use with cardiovascular events and bleeding events in individuals without cardiovascular disease? Findings: In this meta-analysis of 13 trials with 164 225 participants without cardiovascular disease, a...

Evidence of CV benefits of Mediterranean diet growing
https://www.healio.com/cardiology/chd-prevention/news/online/%7B51d6ca5b-5a70-4e7e-ae7b-84b411d0fd62%7D/evidence-of-cv-benefits-of-mediterranean-diet-growing

Jan 5th, 2019 - After the holidays, often as part of a New Year’s resolution, it is common for people to think about changing to a healthier diet. One option is the Mediterranean diet, which was recently named by U.S. News & World Report as the top overall diet, ...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  937 results

Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2...
https://doi.org/10.1161/JAHA.120.016835
Journal of the American Heart Association; Nelson AJ, Ardissino M et. al.

Jan 12th, 2021 - Background Evidence-based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results Pharmac...

Triglycerides as target of cardiovascular risk reduction.
https://doi.org/10.1097/MOL.0000000000000724
Current Opinion in Lipidology FURTHER RECOMMENDED READING; Tietge UJF

Dec 28th, 2020 - Triglycerides as target of cardiovascular risk reduction.|2020|Tietge UJF,|

Advances in the management of statin myopathy.
https://doi.org/10.1097/MED.0000000000000595
Current Opinion in Endocrinology, Diabetes, and Obesity; Gallo A, Perregaux J et. al.

Dec 5th, 2020 - Statins are highly effective therapies for reducing low-density lipoprotein cholesterol and preventing cardiovascular events. However, many patients taking statins experience statin-associated muscle symptoms. In the current manuscript, we review ...

EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.
https://doi.org/10.1016/S2213-8587(20)30368-5
The Lancet. Diabetes & Endocrinology; Aroda VR, Sabatine MS

Nov 20th, 2020 - EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.|2020|Aroda VR,Sabatine MS,|

Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications...
https://doi.org/10.1016/j.jacc.2020.09.004
Journal of the American College of Cardiology; Januzzi JL, Xu J et. al.

Oct 30th, 2020 - Canagliflozin reduces cardiovascular events including hospitalization for heart failure (HHF) in patients with type 2 diabetes and cardiovascular risk. Elevated amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associate...

see more →

News  93 results

How Real-world Data Augments What We Know About SGLT-2 Inhibitors for Cardiovascular Risk Reduction
https://www.medscape.com/viewarticle/937947

Oct 11th, 2020 - Multiple clinical trials demonstrate the efficacy of sodium-glucose co-transporter-2 (SGLT-2) inhibitors to reduce cardiovascular events in persons with diabetes.[1,2,3,4] Use of these agents has been associated with consistent reductions in the c...

2020 ADA Standards: A 'New Concept' in Treating T2D
https://www.medscape.com/viewarticle/924308

Feb 27th, 2020 - This transcript has been edited for clarity. Today I'm going to continue my overview of the 2020 American Diabetes Association (ADA) Standards of Medical Care in Diabetes. Pharmacologic approaches to the management of glycemia in patients with typ...

New Vascepa Approval Opens Up Treatment to Millions
https://www.staging.medscape.com/viewarticle/922865

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...

New Vascepa Approval Opens Up Treatment to Millions
https://www.medscape.com/viewarticle/922865

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...

Icosapent ethyl approved for cardiovascular risk reduction
https://www.mdedge.com/emergencymedicine/article/214314/lipid-disorders/icosapent-ethyl-approved-cardiovascular-risk?channel=39313
Catherine Hackett

Dec 13th, 2019 - Icosapent ethyl (Vascepa) has gained an indication from the Food and Drug Administration for reduction of cardiovascular events in patients with high triglycerides who are at high risk for cardiovascular events. Olivier Le Moal/Getty Images It is.

see more →